Host Cell Proteins: The Hidden Side of Biosimilarity Assessment

Visser, 2013, Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab, BioDrugs, 27, 495, 10.1007/s40259-013-0036-3 European Medicines Agency Committee for Medicinal Products for Human Use CHMP, 2014 Food and Drug Administration, 2015 Reichert, 2011, Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe. February 3–4, 2011, Freiburg, Germany, MAbs, 3, 223, 10.4161/mabs.3.3.15475 Gutierrez, 2012, Of [hamsters] and men: A new perspective on host cell proteins, Hum Vaccin Immunother, 8, 1172, 10.4161/hv.22378 Wang, 2014, Impact of residual impurities and contaminants on protein stability, J Pharm Sci, 103, 1315, 10.1002/jps.23931 Baycin-Hizal, 2012, Proteomic analysis of Chinese hamster ovary cells, J Proteome Res, 11, 5265, 10.1021/pr300476w Krawitz, 2006, Proteomic studies support the use of multi-product immunoassays to monitor host cell protein impurities, Proteomics, 6, 94, 10.1002/pmic.200500225 Lewis, 2013, Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome, Nat Biotechnol, 31, 759, 10.1038/nbt.2624 Tait, 2012, Host cell protein dynamics in the supernatant of a mAb producing CHO cell line, Biotechnol Bioeng, 109, 971, 10.1002/bit.24383 Jin, 2010, Profiling of host cell proteins by two-dimensional difference gel electrophoresis (2D-DIGE): Implications for downstream process development, Biotechnol Bioeng, 105, 306, 10.1002/bit.22532 Yuk, 2015, More similar than different: Host cell protein production using three null CHO cell lines, Biotechnol Bioeng, 112, 2068, 10.1002/bit.25615 Hogwood, 2013, The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process, Biotechnol Bioeng, 110, 240, 10.1002/bit.24607 Zhang, 2014, Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry, MAbs, 6, 659, 10.4161/mabs.28120 Schenauer, 2013, Profiling the effects of process changes on residual host cell proteins in biotherapeutics by mass spectrometry, Biotechnol Prog, 29, 951, 10.1002/btpr.1748 Wang, 2009, Host cell proteins in biologics development: Identification, quantitation and risk assessment, Biotechnol Bioeng, 103, 446, 10.1002/bit.22304 Pharmacopeia, 2014, Chapter <1132>Residual host cell protein measurement in biopharmaceuticals, PF, 40 Zhu-Shimoni, 2014, Host cell protein testing by ELISAs and the use of orthogonal methods, Biotechnol Bioeng, 111, 2367, 10.1002/bit.25327 Champion, 2005, Defining your product profile and maintaining control over it, part 2. Challenges of monitoring host cell protein impurities, BioProcess Int, 3, 52 Reisinger, 2014, A mass spectrometry-based approach to host cell protein identification and its application in a comparability exercise, Anal Biochem, 463, 1, 10.1016/j.ab.2014.06.005 Wang, 2010, Improved HCP quantitation by minimizing antibody cross-reactivity to target proteins, BioProcess Int, 8, 18 Vanderlaan, 2015, Hamster phospholipase B-like 2 (PLBL2), a host cell protein impurity in CHO-derived therapeutic monoclonal antibodies, BioProcess Int, 13, 18 Valente, 2015, Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing, Biotechnol Bioeng, 112, 1232, 10.1002/bit.25515 Bailey-Kellogg, 2014, CHOPPI: A web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production, Biotechnol Bioeng, 111, 2170, 10.1002/bit.25286 Hanania, 2015, Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies, Thorax, 70, 748, 10.1136/thoraxjnl-2014-206719